Joseph Carbone, MD
Urology · Danville, VANPI 1245282458
Payments from drug & device makers
Across 187 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- Neotract Inc.$1K
- Johnson & Johnson$602
- Myriad Genetic Laboratories, Inc.$494
- AbbVie$303
- Axonics, Inc.$287
- plus $2K from 32 others
What the payments were for
- Grants$1212%
- Travel & lodging$1,75928%
- Food & beverage$3,90963%
- Education$3375%
- Other$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 7 | $1,331 |
| Neotract Inc. | 6 | $1,056 |
| Johnson & Johnson | 21 | $602 |
| Myriad Genetic Laboratories, Inc. | 8 | $494 |
| AbbVie(2 entities) | 16 | $303 |
| Axonics, Inc. | 18 | $287 |
| Medtronic(2 entities) | 7 | $208 |
| Sumitomo Pharma America, Inc. | 10 | $193 |
| Bayer | 9 | $179 |
| Vifor Pharma, Inc. | 11 | $172 |
| Myovant Sciences Inc. | 7 | $168 |
| Mallinckrodt Hospital Products Inc. | 5 | $124 |
| Pfizer | 7 | $121 |
| AstraZeneca | 6 | $111 |
| Coloplast | 6 | $95 |
| Blue Earth Diagnostics | 4 | $88 |
| Dendreon Pharmaceuticals LLC | 4 | $85 |
| Accord Healthcare, Inc. | 5 | $85 |
| Merck | 3 | $59 |
| Novartis | 2 | $55 |
| Urogen Pharma, Inc. | 3 | $53 |
| Welch Allyn | 2 | $35 |
| Baxter Healthcare | 2 | $33 |
| Progenics Pharmaceuticals, Inc. | 1 | $28 |
| Ambu Inc. | 2 | $27 |
| Urovant Sciences Inc | 2 | $25 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $22 |
| Akebia Therapeutics Inc | 1 | $18 |
| Rochester Medical Corporation | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Ardelyx, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 2 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
| Immunitybio, Inc. | 1 | $14 |
| Aurinia Pharma U.S., Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Amgen | 1 | $12 |
| Olympus America Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$1,148
- UroLift$1,005
- Prolaris$394
- ORGOVYX$122
How this compares
$6,194 in reported general payments places this provider in the 60th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 47 | $665,513 |
| NubeqaDarolutamide | 25 | $340,336 |
| ErleadaApalutamide | 16 | $235,263 |
| OrgovyxRelugolix | 26 | $68,662 |
| MyrbetriqMirabegron | 71 | $54,861 |
| Estradiol | 77 | $4,986 |
| Oxybutynin Chloride ErOxybutynin Chloride | 279 | $4,686 |
| NitrofurantoinNitrofurantoin Macrocrystal | 91 | $4,108 |
| Finasteride | 324 | $4,047 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 151 | $2,829 |
| Tamsulosin Hcl | 350 | $2,827 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $1,679 |
| Oxybutynin Chloride | 101 | $1,141 |
| Ciprofloxacin Hcl | 134 | $614 |
| Amitriptyline Hcl | 74 | $555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $15 | $720,374118 claims |
| BayerNubeqa | $179 | $340,33625 claims |
| Johnson & JohnsonErleada | $602 | $235,26316 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $193 | $68,66226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 300 urology providers in Virginia.
Other urology in Danville
- Robert GivenVirginia Beach$8.7M
- Michael WilliamsVirginia Beach$2.7M
- Michael FabrizioVirginia Beach$1.6M
- Gregg EureVirginia Beach$1.5M
- Nilay GandhiWoodbridge$1.3M
- Jessica DelongVirginia Beach$644K
- Eugene KramolowskyRichmond$594K
- Nicolas OrtizCharlottesville$331K
- Stephen CulpCharlottesville$284K
- Michael FranksRichmond$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.